Medicenna Therapeutics Corp (TSE:MDNA)

Medicenna Therapeutics Corp (MDNA) Stock Price & Analysis


MDNA Stock Chart & Stats

Day’s RangeC$0 - C$0
52-Week RangeC$0.54 - C$2.38
Previous CloseC$0.82
Average Volume (3M)18.98K
Market Cap
Enterprise ValueC$8.91M
Total Cash (Recent Filing)C$36.15M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)-5.1
Jun 28, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding69,637,469
10 Day Avg. Volume16,884
30 Day Avg. Volume18,982
Standard Deviation0.32
Financial Highlights & Ratios
Price to Book (P/B)1.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0




What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was C$0.54 and its highest was C$2.38 in the past 12 months.
    What is Medicenna Therapeutics Corp’s market cap?
    Currently, no data Available
    When is Medicenna Therapeutics Corp’s upcoming earnings report date?
    Medicenna Therapeutics Corp’s upcoming earnings report date is Jun 28, 2023 which is in 27 days.
      How were Medicenna Therapeutics Corp’s earnings last quarter?
      Medicenna Therapeutics Corp released its earnings results on Feb 07, 2023. The company reported -C$0.02 earnings per share for the quarter, beating the consensus estimate of -C$0.043 by C$0.023.
        Is Medicenna Therapeutics Corp overvalued?
        According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Medicenna Therapeutics Corp pay dividends?
          Medicenna Therapeutics Corp does not currently pay dividends.
          What is Medicenna Therapeutics Corp’s EPS estimate?
          Medicenna Therapeutics Corp’s EPS estimate is -C$0.08.
            How many shares outstanding does Medicenna Therapeutics Corp have?
            Medicenna Therapeutics Corp has 54,954,610 shares outstanding.
              What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
              Medicenna Therapeutics Corp reported an EPS of -C$0.02 in its last earnings report, beating expectations of -C$0.043. Following the earnings report the stock price went down -0.99%.
                Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
                Currently, no hedge funds are holding shares in TSE:MDNA


                Medicenna Therapeutics Corp Stock Smart Score

                Not Ranked
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Medicenna Therapeutics Corp

                Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Microbix Biosystms
                Covalon Technologies
                Helix BioPharma
                Sirona Biochem

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis